Original article by The Neuro....
Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...
Career of breakthroughs in neuroimaging recognized with one of the nation鈥檚 highest honours ...
Study has implications beyond medical education, suggesting other fields could benefit from AI-enhanced training...
Mapping immune cell diversity reveals dexamethasone鈥檚 impact on brain cancer immunotherapy...
Free, online training program strengthens training and brings specialized care to communities across Quebec...
$400,000 will fuel public-private collaboration to discover new disease biomarkers...
NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians...
Projects include important research on Parkinson鈥檚, glioblastoma and dementia 聽
RSS